119 Publications in Distinguished Journals in 2020

Trust your cancer care to our providers at West Cancer Center & Research Institute who authored 119 publications in distinguished medical journals in 2020 alone. We are standing behind our name and respected by leaders in oncology care.

1. Matthew Ballo:
   • VanderWalde NA, Martin MY, Kocak M, Morningstar C, Deal AM, Nyrop KA, Farmer M, Ballo M, VanderWalde A, Muss H. Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older adult breast cancer patients. J Geriatr Oncol. 2020 Sep 22:S1879-4068(20)30440-9. doi: 10.1016/j.jgo.2020.09.013. Epub ahead of print. PMID: 32978102.
   • Lacouture ME, Anadkat MJ, Ballo MT, Iwamoto F, Jeyapalan SA, La Rocca RV, Schwartz M, Serventi JN, Glas M. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. Front Oncol. 2020 Jul 28;10:1045. doi: 10.3389/fonc.2020.01045. PMID: 32850308; PMCID: PMC7399624.
2. *Michael Berry:
   • Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017. PMID: 32259785.
   • Jain AL, Mullins J, Smith JR, Valasareddy P, Miller E, Chaudhry A, Ryder J, Hare F, Ranganath H, Berry M, Robins D, Schwartzberg L, Vidal GA. Unusual recurrent metastasizing benign breast papilloma: a case report. J Med Case Rep. 2020 Feb 19;14(1):33. doi: 10.1186/s13256-020-2354-7. PMID: 32070435; PMCID: PMC7029571.
3. Jason Chandler:
   • Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Dec 2;18(12):1685-1717. doi: 10.6004/jnccn.2020.0057. PMID: 33285522.
   • Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 Nov 20;38(33):3863-3873. doi: 10.1200/JCO.20.00131. Epub 2020 Sep 10. PMID: 32910710; PMCID: PMC7676888.
4. Adam ElNaggar:
   • VanderWalde, A. Grothey, D. Vaena, G. Vidal, A.C. ElNaggar, G. Bufalino, L. Schwartzberg. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J. Pers. Med. 2020, 10(4), 252. doi: 10.3390/jpm10040252. PMID: 33260805
   • Oaknin, A., C. F. Friedman, L. D. Roman, A. D’Souza, I. Brana, F. Clement-Bidard, J. Goldman, E. A. Alvarez, V. Boni, C. ElNaggar, R. Passalacqua, K. T. M. Do, A. D. Santin, K. Keyvanjah, F. Xu, L. D. Eli, A. S. Lalani, R. P. Bryce, D. M. Hyman, F. Meric-Bernstam, D. B. Solit and B. J. Monk (2020). “Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.” Gynecol Oncol. doi:10.1016/j.ygyno.2020.07.025. PMID: 32723675
   • Ulm, T. Redfern, B. Wilson, S. Ponnusamy, S. Asemota, P. Blackburn, Y. Wang, A.C. ElNaggar, R. Narayanan. Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer. J. Pers. Med. 2020, 10(4), 246. doi.org/10.3390/jpm10040246. PMID: 33256002
5. Michael Farmer:
   • VanderWalde NA, Martin MY, Kocak M, Morningstar C, Deal AM, Nyrop KA, Farmer M, Ballo M, VanderWalde A, Muss H. Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older adult breast cancer patients. J Geriatr Oncol. 2020 Sep 22:S1879-4068(20)30440-9. doi: 10.1016/j.jgo.2020.09.013. Epub ahead of print. PMID: 32978102.
6. Axel Grothey:
   • Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O’Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, André T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2020 Dec 23:JCO2001600. doi: 10.1200/JCO.20.01600. Online ahead of print.PMID: 33356421
   • Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clin Cancer Res. 2020 Dec 8. doi: 10.1158/1078-0432.CCR-20-3286. Online ahead of print.PMID: 33293373
   • Grothey A. Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer – A New Standard of Care. N Engl J Med. 2020 Dec 3;383(23):2283-2285. doi: 10.1056/NEJMe2031294.PMID: 33264550
   • VanderWalde N, Grothey A. Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way. JAMA Netw Open. 2020 Dec 1;3(12):e2030508. doi: 10.1001/jamanetworkopen.2020.30508. PubMed PMID: 33326022.
   • André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020 Dec;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1.PMID: 33271092
   • VanderWalde A, Grothey A, Vaena D, Vidal G, ElNaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med. 2020 Nov 27;10(4). doi: 10.3390/jpm10040252. PubMed PMID: 33260805; PubMed Central PMCID: PMC7711773.
   • Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G. Molecular characteristics of BRCA1/2and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.PMID: 33229504
   • Sobrero AF, Puccini A, Shi Q, Grothey A, Andrè T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, Bruzzi P. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020 Oct;138:182-188. doi: 10.1016/j.ejca.2020.07.031. Epub 2020 Sep 3.PMID: 32892120
   • Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, Grothey A, Somer BG, Dickson PV.Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Ann Surg Oncol. 2020 Aug 27:1-11. doi: 10.1245/s10434-020-09045-w. Online ahead of print.PMID: 32856227
   • Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O’Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. J Natl Cancer Inst. 2020 Aug 24:djaa124. doi: 10.1093/jnci/djaa124. Online ahead of print.PMID: 32835356
   • Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. 2020 Sep;25(9):e1426-e1427. doi: 10.1634/theoncologist.2020-0451. Epub 2020 Jul 7.PMID: 32536024
   • Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020 Nov 15;147(10):2948-2956. doi: 10.1002/ijc.33115. Epub 2020 Jun 18.PMID: 32449172
   • Grothey A. EGFR inhibition in colorectal cancer with liver metastasis. Clin Adv Hematol Oncol. 2020 Jun;18(6):319-321. PMID: 32649654
   • Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushmann M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz H, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.PMID: 32576609
   • Corcoran RB, Grothey A. Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction? JAMA Oncol. 2020 Jun 1;6(6):823-824. doi: 10.1001/jamaoncol.2020.0504. PMID: 32379270
   • Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, Seeber A. WRN-Mutated Colorectal Cancer Is Characterized by aDistinct Genetic Phenotype. Cancers (Basel). 2020 May 22;12(5):1319. doi: 10.3390/cancers12051319.PMID: 32455893
   • Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. APractical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. 2020 Jun;25(6):e936-e945. doi: 10.1634/theoncologist.2020-0213. Epub 2020 Apr 27.PMID: 32243668
   • Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 May;130:63-71. doi: 10.1016/j.ejca.2020.02.009. Epub 2020 Mar 12.PMID: 32172199
   • Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, Dickson PV, Glazer ES, Yakoub D, Shibata D, Grothey AF, Philip PA, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ, Deneve JL. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. .J Surg Oncol. 2020 Jun;121(8):1320-1328. doi: 10.1002/jso.25899. Epub 2020 Mar 12.PMID: 32166754
   • Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol. 2020 Mar 6;12:1758835920910913. doi: 10.1177/1758835920910913. eCollection 2020.PMID: 32201506
   • Kopetz S, Grothey A, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply. N Engl J Med. 2020 Feb 27;382(9):877-878. doi: 10.1056/NEJMc1915676.PMID: 32101678
   • Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020 Jun;86:101993. doi: 10.1016/j.ctrv.2020.101993. Epub 2020 Feb 20.PMID: 32199197
   • Gholami S, Grothey A. EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit? Lancet Oncol. 2020 Mar;21(3):324-326. doi: 10.1016/S1470-2045(20)30003-6. Epub 2020 Jan 31.PMID: 32014120
   • Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16.PMID: 32085892
   • Kasi PM, Grothey A. Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Ann Oncol. 2020 Jan;31(1):15-16. doi: 10.1016/j.annonc.2019.11.001.PMID: 31912790
   • Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. 2020 May;25(5):404-413. doi: 10.1634/theoncologist.2019-0552. Epub 2019 Dec 17.PMID: 31848314
   • McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME.Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21.PMID: 31787526
7. Clay Jackson:
   • Jackson WC. Connecting the dots:  how adverse childhood experiences predispose to chronic pain. Practical Pain Management 2020;20(3):24-28.. 
   • Trivedi MH, Papakostas GI, Jackson WC, Rafeyan R. Implementing measurement-based care to determine and treat inadequate respo J Clin Psychiatry. 2020 May 5;81(3):OT19037BR1. doi: 10.4088/JCP.OT19037BR1.PMID: 32369683. 
   • Rafayen R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate response to treatment in major depressive disorder:  augmentation and adjunctive strategies J Clin Psychiatr 2020 May 19;81(3):OT19037COM5. doi: 10.4088/JCP.OT19037COM5.PMID: 32433833
   • Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH. Overcoming challenges to treat inadequate response in major depressive disorder. J Clin Psychiatry. 2020 May 12;81(3):OT19037BR4. doi: 10.4088/JCP.OT19037BR4.
   • Jackson WC, Papakostas GI, Rafeyan R, Trivedi MH. Recognizing inadequate response in patients with major depressive disorder. J Clin Psychiatry. 2020 May 5;81(3):OT19037BR2. doi: 10.4088/JCP.OT19037BR2.PMID: 32369684
8. Robert Johnson:
   • Otieno SB, Nasir S, Weir A, Johnson R. Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors. Case Rep Hematol. 2020 Dec 11;2020:8821415. doi: 10.1155/2020/8821415. PMID: 33381330; PMCID: PMC7748897.
9. Michael G. Martin:
   • Morris LK, Altahan A, Gandhi J, Mays J, Giri U, Fleming M, Martin MG. Impact of margin status on survival after radical nephrectomy for renal cell carcinoma. J Surg Oncol. 2020 Dec 17. doi: 10.1002/jso.26321. Epub ahead of print. PMID: 33333591.
   • Altahan A, Harris LJ, Porta J, Jain AL, Martin MG. Association Between Pesticide Use and Incidence of Diffuse Large B-Cell Lymphoma. Anticancer Res. 2020 Oct;40(10):5423-5426. doi: 10.21873/anticanres.14552. PMID: 32988863.
   • Adeniji AA, Dawodu OO, Habeebu MY, Oyekan AO, Bashir MA, Martin MG, Keshinro SO, Fagbenro GT. Distribution of Breast Cancer Subtypes Among Nigerian Women and Correlation to the Risk Factors and Clinicopathological Characteristics. World J Oncol. 2020 Aug;11(4):165-172. doi: 10.14740/wjon1303. Epub 2020 Aug 10. PMID: 32849957; PMCID: PMC7430856.
   • Dulal S, Paudel BD, Wood LA, Neupane P, Shah A, Acharya B, Shilpakar R, Acharya SC, Karn A, Poudel B, Thapa RR, Acharya A, Martin MG. Reliance on Self-Medication Increase Delays in Diagnosis and Management of GI Cancers: Results From Nepal. JCO Glob Oncol. 2020 Aug;6:1258-1263. doi: 10.1200/GO.20.00202. PMID: 32762562; PMCID: PMC7456311.
   • Dulal S, Adeniji AA, Martin MG. Feasibility of Fewer Fraction Palliative Radiotherapy in Resource-Limited Setting. World J Oncol. 2020 Apr;11(2):76-77. doi: 10.14740/wjon1271. Epub 2020 Mar 29. PMID: 32284776; PMCID: PMC7141159.
   • Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, Dickson PV, Glazer ES, Yakoub D, Shibata D, Grothey AF, Philip PA, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ, Deneve JL. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. J Surg Oncol. 2020 Jun;121(8):1320-1328. doi: 10.1002/jso.25899. Epub 2020 Mar 12. PMID: 32166754; PMCID: PMC7505122.
   • Stein MK, Morris LK, Martin MG. Next-Generation Sequencing Identifies Novel RTK VUSs in Breast Cancer with an Emphasis on ROS1, ERBB4, ALK and NTRK3. Pathol Oncol Res. 2020 Jan;26(1):593-595. doi: 10.1007/s12253-018-0550-1. Epub 2018 Nov 20. PMID: 30460540.
10. Sameer Nasir:
    • Otieno SB, Nasir S, Weir A, Johnson R. Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors. Case Rep Hematol. 2020 Dec 11;2020:8821415. doi: 10.1155/2020/8821415. PMID: 33381330; PMCID: PMC7748897.
    • Delgado-Ramos GM, Nasir SS, Wang J, Schwartzberg LS. Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women. Breast Cancer Res Treat. 2020 Jul;182(2):247-258. doi: 10.1007/s10549-020-05684-5. Epub 2020 May 23. PMID: 32447595.
11. Arnel Pallera:
    • Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047. PMID: 33022644.
12. Manjari Pandey:
    • Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052. PMID: 33152694.
    • Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger AB. Primary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa018. doi: 10.1093/noajnl/vdaa018. Epub 2020 Feb 19. PMID: 32201861; PMCID: PMC7067145.
13. Jason Porter:
    • Owsley J, Stein MK, Porter J, In GK, Salem M, O’Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021 Jan;246(1):31-39. doi: 10.1177/1535370220959657. Epub 2020 Oct 5. PubMed PMID: 33019809; PubMed Central PMCID: PMC7797994.
14. Sylvia Richey:
    • McAneny B, Schwartzberg L, Koh W-J, Arrowsmith E, Fugaro A, Haydell T, Heskeeth PJ, Pudusseri A, Richey S, Zarwan C, Stein R. Supporting optimal, value-based, and sustainable cancer care delivery. J Clin Pathways 2020;6(8):58-61. doi:10.25270/jcp.2020.10.00002.
15. David B. Robins:
    • Jain AL, Mullins J, Smith JR, Valasareddy P, Miller E, Chaudhry A, Ryder J, Hare F, Ranganath H, Berry M, Robins D, Schwartzberg L, Vidal GA. Unusual recurrent metastasizing benign breast papilloma: a case report. J Med Case Rep. 2020 Feb 19;14(1):33. doi: 10.1186/s13256-020-2354-7. PMID: 32070435; PMCID: PMC7029571.
16. Alex Ryder:
    • Hauser RG, Kwon RJ, Ryder A, Cheng C, Charifa A, Tormey C. Transfusion Medicine Equations Made Internet Accessible. Transfus Med Rev. 2020 Jan;34(1):5-9. doi: 10.1016/j.tmrv.2019.10.003. Epub 2019 Nov 16. PMID: 31785949.
    • Nagel MB, Ryder A, Lobbins M, Bhatt N. Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus. Pediatr Blood Cancer. 2021 Jan;68(1):e28534. doi: 10.1002/pbc.28534. Epub 2020 Jul 13. PMID: 32658352.
17. Lee Schwartzberg:
    • Navari RM, Ruddy KJ, LeBlanc TW, Nipp R, Clark-Snow R, Schwartzberg L, Binder G, Bailey WL, Potluri R, Schmerold LM, Papademetriou E, Roeland EJ. Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin. 2020 Dec 1. doi: 10.1002/onco.13620. Online ahead of print.PMID: 33289268
    • VanderWalde A, Grothey A, Vaena D, Vidal G, ElNaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med. 2020 Nov 27;10(4):252. doi: 10.3390/jpm10040252.PMID: 33260805
    • Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Future Oncol. 2020 Nov 19. doi: 10.2217/fon-2020-1021. Online ahead of print.PMID: 33207944
    • Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. J Comp Eff Res. 2020 Nov 10. doi: 10.2217/cer-2020-0213. Online ahead of print.PMID: 33167695
    • Aapro M, Navari RM, Roeland E, Zhang L, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK₁/5-HT₃receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan;157:103143. doi: 10.1016/j.critrevonc.2020.103143. Epub 2020 Nov 7.PMID: 33260048
    • Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O’Brien T, Kelly CM, Winer E, Yardley DA. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Dec 1;26(23):6149-6157. doi: 10.1158/1078-0432.CCR-20-1693. Epub 2020 Sep 28.PMID: 32988969
    • Miller E, Schwartzberg L. Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood. Curr Treat Options Oncol. 2020 Sep 1;21(11):89. doi: 10.1007/s11864-020-00783-3. PMID: 32875404
    • Khoury K, Tan AR, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn WM, Swain SM, Lynce F. Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. Front Oncol. 2020 Aug 31;10:1475. doi: 10.3389/fonc.2020.01475. eCollection 2020. PMID: 32983983
    • Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, Isaacs C, Swain SM, Vidal G, Schwartzberg LS, Tan AR. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat. 2020 Nov;184(2):265-275. doi: 10.1007/s10549-020-05849-2. Epub 2020 Aug 10.PMID: 32776290
    • Cobb PW, Moon YW, Mezei K, Láng I, Bhat G, Chawla S, Hasal SJ, Schwartzberg LS. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study. Cancer Med. 2020 Sep;9(17):6234-6243. doi: 10.1002/cam4.3227. Epub 2020 Jul 20.PMID: 32687266
    • Schwartzberg LS, Horinouchi H, Chan D, Chernilo S, Tsai ML, Isla D, Escriu C, Bennett JP, Clark-Langone K, Svedman C, Tomasini P; Oncotype SEQ® Study Investigators and Program Team. Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. NPJ Precis Oncol. 2020 Jun 24;4:15. doi: 10.1038/s41698-020-0118-x. eCollection 2020.PMID: 32596507
    • Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial. 2020 Aug;25(8):e1233-e1241. doi: 10.1634/theoncologist.2020-0105. Epub 2020 Jun 16.PMID: 32476162
    • Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S, Potluri R, Schmerold L, Papademetriou E, Schwartzberg L, Navari RM. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 Jun;18(6):676-681. doi: 10.6004/jnccn.2019.7526.PMID: 32502985
    • Delgado-Ramos GM, Nasir SS, Wang J, Schwartzberg LS. Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women. Breast Cancer Res Treat. 2020 Jul;182(2):247-258. doi: 10.1007/s10549-020-05684-5. Epub 2020 May 23.PMID: 32447595
    • Anderson JN, Graff JC, Krukowski RA, Schwartzberg L, Vidal GA, Waters TM, Paladino AJ, Jones TN, Blue R, Kocak M, Graetz I. “Nobody Will Tell You. You’ve Got to Ask!”: An Examination of Patient-provider Communication Needs and Preferences among Black and White Women with Early-stage Breast Cancer. Health Commun. 2020 Apr 26:1-12. doi: 10.1080/10410236.2020.1751383. Online ahead of print.PMID: 32336140
    • Jain AL, Jamy O, Mullins J, Usman RM, Hare F, Valasareddy P, Chaudhry A, Ryder J, Smith JR, Miller E, Ranganath H, Schwartzberg L, Stepanski E, Walker M, Gatwood J, Vidal GA. Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer. Proc (Bayl Univ Med Cent). 2020 Apr 7;33(3):331-335. doi: 10.1080/08998280.2020.1744059. eCollection 2020 Jul.PMID: 32675948
    • Schwartzberg LS, Vidal GA. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Clin Breast Cancer. 2020 Aug;20(4):e439-e449. doi: 10.1016/j.clbc.2020.02.002. Epub 2020 Feb 20.PMID: 32278641
    • Jain AL, Mullins J, Smith JR, Valasareddy P, Miller E, Chaudhry A, Ryder J, Hare F, Ranganath H, Berry M, Robins D, Schwartzberg L, Vidal GA. Unusual recurrent metastasizing benign breast papilloma: a case report. J Med Case Rep. 2020 Feb 19;14(1):33. doi: 10.1186/s13256-020-2354-7.PMID: 32070435
    • Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 Jun;20(3):183-193. doi: 10.1016/j.clbc.2020.01.001. Epub 2020 Jan 8. PMID: 32014370
    • Soliman H, Wagner S, Flake DD 2nd, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Ann Surg Oncol. 2020 Mar;27(3):765-771. doi: 10.1245/s10434-019-08039-7. Epub 2020 Jan 6. PMID: 31907749
    • Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. 2020 Mar;25(3):e589-e597. doi: 10.1634/theoncologist.2019-0527. Epub 2019 Dec 8. PMID: 32162813
    • Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. Epub 2019 Dec 5. PMID: 31806627
    • Skinner KE, Olufade T, Walker MS, Schwartzberg LS. Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer. Breast J. 2020 Feb;26(2):112-119. doi: 10.1111/tbj.13492. Epub 2019 Sep 17.PMID: 31531938
    • Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 Jun;20(3):e251-e260. doi: 10.1016/j.clbc.2019.08.001. Epub 2019 Aug 21.PMID: 32139271
18. Courtney Shires:
    • Klug TD, Craig J, Shires CB. Awake ECMO without anticoagulation for nearly completely obstructive squamous cell carcinoma of the trachea. Clin Case Rep. 2020 Nov 6;9(1):164-168. doi: 10.1002/ccr3.3490. PMID: 33489153; PMCID: PMC7813012.
    • Klug T, Sebelik M, Shires CB. Chyloma formation after anterior cervical disc fusion. Clin Case Rep. 2020 Aug 26;8(12):2721-2724. doi: 10.1002/ccr3.3274. PMID: 33363812; PMCID: PMC7752606.
    • Shires CB, Klug T, Shete M, Sebelik M. Multiplanar Computed Tomography Reconstruction to Diagnose Lemierre’s Syndrome. OTO Open. 2020 Jul 8;4(3):2473974X20940692. doi: 10.1177/2473974X20940692. PMID: 32685872; PMCID: PMC7346694.
19. *Bradley G. Somer:
    • Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 Sep;18(9):1160-1170. doi: 10.6004/jnccn.2020.0043. PMID: 32886895
    • Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, Grothey A, Somer BG, Dickson PV. Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Ann Surg Oncol. 2020 Aug 27:1-11. doi: 10.1245/s10434-020-09045-w. Online ahead of print. PMID: 3285622
    • McFarlane JJ, Kochenderfer MD, Olsen MR, Bauer TM, Molina A, Hauke RJ, Reeves JA, Babu S, Van Veldhuizen P, Somer B, Gunuganti V, Schnadig I, George S, Page RD, Arrowsmith E, Jain RK, Zhang J, McHenry MB, Johansen JL, Vogelzang NJ. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 Dec;18(6):469-476.e4. doi: 10.1016/j.clgc.2020.06.002. Epub 2020 Jun 14. PMID: 32641261
    • Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD, Molina A, Doshi G, Lingerfelt B, Hauke RJ, Gunuganti V, Schnadig I, Van Veldhuizen P, Fleming M, Galamaga R, Gupta M, Hool H, Hutson T, Zhang J, McHenry MB, Johansen JL, Tykodi SS. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 Dec;18(6):461-468.e3. doi: 10.1016/j.clgc.2020.05.006. Epub 2020 May 16. PMID: 32718906
    • Drake JA, Stiles ZE, Behrman SW, Glazer ES, Deneve JL, Somer BG, Vanderwalde NA, Dickson PV. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? HPB (Oxford). 2020 Nov;22(11):1530-1541. doi: 10.1016/j.hpb.2020.02.011. Epub 2020 Mar 21. PMID: 32209323
    • Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. 2020 Jan;80(1):99-108. doi: 10.1002/pros.23922. Epub 2019 Nov 19. PMID: 31742767
20. Todd Tillmanns:
    • Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020 Jun;18(6):660-666. doi: 10.6004/jnccn.2020.0027. PMID: 32502976.
21. Michael Ulm:
    • Ulm, T. Redfern, B. Wilson, S. Ponnusamy, S. Asemota, P. Blackburn, Y. Wang, A.C. ElNaggar, R. Narayanan. Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer. J. Pers. Med. 2020, 10(4), 246. doi.org/10.3390/jpm10040246. PMID: 33256002
22. Daniel Vaena:
    • VanderWalde A, Grothey A, Vaena D, Vidal G, ElNaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med. 2020 Nov 27;10(4):252. doi: 10.3390/jpm10040252. PMID: 33260805; PMCID: PMC7711773.
    • Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G, DeBenedette M, Gamble A, Plachco A, Norris MS, Horvatinovich J, Tcherepanova IY, Nicolette CA, Wood CG; ADAPT study group. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 May 15;26(10):2327-2336. doi: 10.1158/1078-0432.CCR-19-2427. Epub 2020 Feb 7. PMID: 32034074.
    • Stein J, Milhem M, Vaena D. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature. J Oncol Pharm Pract. 2020 Jan;26(1):232-235. doi: 10.1177/1078155219841108. Epub 2019 Apr 8. PMID: 30961437.
23. Ari VanderWalde: https://www.ncbi.nlm.nih.gov/myncbi/1nS9yizO-lrAZ/bibliography/public/
    • Owsley J, Stein MK, Porter J, In GK, Salem M, O’Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021 Jan;246(1):31-39. doi: 10.1177/1535370220959657. Epub 2020 Oct 5. PubMed PMID: 33019809; PubMed Central PMCID: PMC7797994.
    • Borden BA, Baca Y, Xiu J, Tavora F, Winer I, Weinberg BA, Vanderwalde AM, Darabi S, Korn WM, Mazar AP, Giles FJ, Crawford L, Safran H, El-Deiry WS, Carneiro BA. The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Mol Cancer Ther. 2021 Jan;20(1):183-190. doi: 10.1158/1535-7163.MCT-20-0497. Epub 2020 Oct 21. PubMed PMID: 33087512.
    • VanderWalde A, Grothey A, Vaena D, Vidal G, ElNaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med. 2020 Nov 27;10(4). doi: 10.3390/jpm10040252. PubMed PMID: 33260805; PubMed Central PMCID: PMC7711773.
    • VanderWalde NA, Martin MY, Kocak M, Morningstar C, Deal AM, Nyrop KA, Farmer M, Ballo M, VanderWalde A, Muss H. Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older adult breast cancer patients. J Geriatr Oncol. 2020 Sep 22;. doi: 10.1016/j.jgo.2020.09.013. [Epub ahead of print] PubMed PMID: 32978102.
    • Saul M, Poorman K, Tae H, Vanderwalde A, Stafford P, Spetzler D, Korn WM, Gatalica Z, Swensen J. Population bias in somatic measurement of microsatellite instability status. Cancer Med. 2020 Sep;9(17):6452-6460. doi: 10.1002/cam4.3294. Epub 2020 Jul 9. PubMed PMID: 32644297; PubMed Central PMCID: PMC7476819.
    • In GK, Poorman K, Saul M, O’Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A.Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18;11(33):3118-3128. doi: 10.18632/oncotarget.27686. eCollection 2020 Aug 18. PubMed PMID: 32913556; PubMed Central PMCID: PMC7443369.
24. Noam VanderWalde: https://www.ncbi.nlm.nih.gov/myncbi/1PUcZ0u3y-tAo/bibliography/public/
    • VanderWalde NA, Williams GR. Developing an electronic geriatric assessment to improve care of older adults with cancer receiving radiotherapy. Tech Innov Patient Support Radiat Oncol. 2020 Dec;16:24-29. doi: 10.1016/j.tipsro.2020.09.002. eCollection 2020 Dec. PubMed PMID: 33385071; PubMed Central PMCID: PMC7769846.
    • VanderWalde N, Grothey A. Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way. JAMA Netw Open. 2020 Dec 1;3(12):e2030508. doi: 10.1001/jamanetworkopen.2020.30508. PubMed PMID: 33326022.
    • Drake JA, Stiles ZE, Behrman SW, Glazer ES, Deneve JL, Somer BG, Vanderwalde NA, Dickson PV. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? HPB (Oxford). 2020 Nov;22(11):1530-1541. doi: 10.1016/j.hpb.2020.02.011. Epub 2020 Mar 21. PubMed PMID: 32209323.
    • Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rödel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw. 2020 Oct;18(10):1322-1326. doi: 10.6004/jnccn.2020.7578. Print 2020 Oct. PubMed PMID: 33022640.
    • VanderWalde NA, Martin MY, Kocak M, Morningstar C, Deal AM, Nyrop KA, Farmer M, Ballo M, VanderWalde A, Muss H. Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older adult breast cancer patients. J Geriatr Oncol. 2020 Sep 22;. doi: 10.1016/j.jgo.2020.09.013. [Epub ahead of print] PubMed PMID: 32978102.
    • Okonji D, Li D, VanderWalde N, Winer A, Williams GR, Arora SP. Geriatric oncology research presented at the ASCO GI 2020 symposium: Young international society of geriatric oncology perspective paper. J Geriatr Oncol. 2020 Sep;11(7):1182-1186. doi: 10.1016/j.jgo.2020.05.003. Epub 2020 May 14. PubMed PMID: 32418879.
    • Freedman RA, Sedrak MS, Bellon JR, Block CC, Lin NU, King TA, Minami C, VanderWalde N, Jolly TA, Muss HB, Winer EP. Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2020 May 25;. doi: 10.1093/jnci/djaa079. [Epub ahead of print] PubMed PMID: 32449757; PubMed Central PMCID: PMC7313961.
    • Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mandel JJ, Fang P, Smith BD, Smith GL, Pinnix CC, Sedrak MS, Kimmick GG, Stinchcombe TE, Jagsi R, Thomas CR Jr, Fuller CD, VanderWalde NA.Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. J Geriatr Oncol. 2020 Apr;11(3):451-454. doi: 10.1016/j.jgo.2019.11.001. Epub 2019 Nov 8. PubMed PMID: 31711757; PubMed Central PMCID: PMC7370694.
    • Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J. Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. J Geriatr Oncol. 2020 Mar;11(2):179-183. doi: 10.1016/j.jgo.2019.05.011. Epub 2019 Jun 11. PubMed PMID: 31201095; NIHMSID:NIHMS1059482
    • Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst. 2020 Feb 1;112(2):211-213. doi: 10.1093/jnci/djz154. PubMed PMID: 31350545; PubMed Central PMCID: PMC7019091.
25. *Gregory Vidal:
    • McGregor BA, Vidal GA, Shah SA, Mitchell JD, Hendifar AE. Remote Oncology Care: Review of Current Technology and Future Directions. 2020 Aug 31;12(8):e10156. doi: 10.7759/cureus.10156. PMID: 33014652
    • Anderson JN, Graff JC, Krukowski RA, Schwartzberg L, Vidal GA, Waters TM, Paladino AJ, Jones TN, Blue R, Kocak M, Graetz I. “Nobody Will Tell You. You’ve Got to Ask!”: An Examination of Patient-provider Communication Needs and Preferences among Black and White Women with Early-stage Breast Cancer. Health Commun. 2020 Apr 26:1-12. doi: 10.1080/10410236.2020.1751383. Online ahead of print. PMID: 32336140
    • Jain AL, Jamy O, Mullins J, Usman RM, Hare F, Valasareddy P, Chaudhry A, Ryder J, Smith JR, Miller E, Ranganath H, Schwartzberg L, Stepanski E, Walker M, Gatwood J, Vidal GA. Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer. Proc (Bayl Univ Med Cent). 2020 Apr 7;33(3):331-335. doi: 10.1080/08998280.2020.1744059. eCollection 2020 Jul. PMID: 3267594
    • Schwartzberg LS, Vidal GA. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Clin Breast Cancer. 2020 Aug;20(4):e439-e449. doi: 10.1016/j.clbc.2020.02.002. Epub 2020 Feb 20. PMID: 32278641
    • Jain AL, Mullins J, Smith JR, Valasareddy P, Miller E, Chaudhry A, Ryder J, Hare F, Ranganath H, Berry M, Robins D, Schwartzberg L, Vidal GA. Unusual recurrent metastasizing benign breast papilloma: a case report. J Med Case Rep. 2020 Feb 19;14(1):33. doi: 10.1186/s13256-020-2354-7. PMID: 32070435